A novel GPR84 antagonist attenuates diabetic lung injury by inhibiting pyroptosis via the cGAS-STING pathway in pulmonary vascular endothelial cells
International Immunopharmacology · 2025-10 · 163 · 115190
DOI: 10.1016/j.intimp.2025.115190 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025-10. Verfasst von Wei Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Dalian Medical University, Dalian Medical University, Dalian 116044, China. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Endothelial Cells, Lung Injury, Nucleotidyltransferases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Abstract (Originalsprache)
Diabetic lung injury (DLI) is a severe complication of diabetes, characterized by pulmonary vascular endothelial cell damage, inflammation, and pyroptosis. However, the underlying molecular mechanisms remain unclear. This study investigates the role of G-protein-coupled receptor 84 (GPR84) in DLI and its regulation of pyroptosis via the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway. We first established a DLI rat model and found that GPR84 expression was significantly upregulated in lung tissue. RNA sequencing and bioinformatics analysis identified a strong correlation between GPR84 and cGAS-STING pathway-related genes, including TBK1, CGAS, IFNA2, and STING1. Molecular docking analysis revealed that β-sitosterol, a natural compound from Sophora japonica, exhibited strong binding affinity to GPR84. In vitro experiments demonstrated that β-sitosterol effectively inhibited the cGAS-STING pathway, reducing pyroptosis and inflammatory cytokine secretion in pulmonary vascular endothelial cells. Furthermore, in vivo studies confirmed that β-sitosterol administration significantly attenuated lung inflammation, suppressed cGAS-STING activation, and reduced pyroptosis in diabetic rats. These findings highlight β-sitosterol as a novel GPR84 antagonist with therapeutic potential for mitigating DLI by inhibiting cGAS-STING-mediated pyroptosis. This study provides new insights into the pathogenesis of diabetic lung injury and potential molecular targets for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Dalian Medical University, Dalian Medical University, Dalian 116044, China.
- Department of Endocrinology, General Hospital of Northern Theater Command, Shenyang 110016, China.
- Department of Respiratory Medicine, General Hospital of Northern Theater Command, Shenyang 110016, China. Electronic address: ma-tianyi@163.com.
Zitieren
APA
Gao, W., Tong, H., Yu, H., Chen, R., Wang, Y., Liang, L., Li, Y., & Ma, Z. (2025). A novel GPR84 antagonist attenuates diabetic lung injury by inhibiting pyroptosis via the cGAS-STING pathway in pulmonary vascular endothelial cells. International Immunopharmacology, 163, 115190. https://doi.org/10.1016/j.intimp.2025.115190
Vancouver
Gao W, Tong H, Yu H, Chen R, Wang Y, Liang L, et al. A novel GPR84 antagonist attenuates diabetic lung injury by inhibiting pyroptosis via the cGAS-STING pathway in pulmonary vascular endothelial cells. International Immunopharmacology. 2025;163:115190. doi:10.1016/j.intimp.2025.115190
BibTeX
@article{Gao2025,
author = {Gao, Wei and Tong, Huixin and Yu, Hao and Chen, Ruoran and Wang, Yu and Liang, Linlang and Li, Yiyao and Ma, Zhuang},
title = {A novel GPR84 antagonist attenuates diabetic lung injury by inhibiting pyroptosis via the cGAS-STING pathway in pulmonary vascular endothelial cells},
journal = {International Immunopharmacology},
year = {2025},
volume = {163},
pages = {115190},
doi = {10.1016/j.intimp.2025.115190}
}
EUVIMED